Board
Dr Doug Wilson MB, ChB, PhD, FRACP, FRCPA Dr Doug Wilson is the former Senior Vice President for Medicine and Regulatory Affairs for Boehringer Ingelheim, USA, overseeing all clinical research programmes and interactions with FDA. During this period he was part of a lead team that saw 10 drugs complete successful NDAs and go onto the US market. He then became responsible for the same functions world-wide at the Companys head office in Ingelheim, Germany. He was deputy chair for some years of the companys International Medical Committee which oversaw all drugs in development globally and would assess up to 50 or more projects on a regular basis. He chaired the companys International Labeling Committee which oversaw all drug labeling and safety for drugs around the world and was a core membber of the companys International Steering Committee which supervised the companys major financial investments globally. Since his return to New Zealand he has consulted with a number of biotech groups in Australia, New Zealand and the USA and is also on the board of Neuren Pharmaceutical.
Dr Watt is the CEO and CSO of Phylogica. He is key inventor of Phylogica’s drug discovery technologies, has published 45 papers, and has filed more than 19 patent applications many of which are granted in the US and Europe. Specialising in drug discovery biotechnology and experimental genetics, he has attracted over $5 million in research funding from Australia and the United States for the technology underpinning Phylogica. A leading graduate from The University of Western Australia, Paul Watt completed his doctorate in Molecular Biology at Oxford University before taking up postdoctoral appointments in yeast genetics at Harvard and Oxford Universities where he discovered and characterised proteins involved in maintaining genome stability. As an Honorary Research fellow at the Telethon Institute for Child Health Research, he was appointed Adjunct Professor at the school of Paediatrics and Child Health of the University for Western Australia. Professor Watt also founded InfaMed Ltd., now owned by Cambridge, UK-based Avita Medical Ltd, which is commercialising an FDA-approved/CE-marked paediatric drug delivery device he invented, which is currently marketed internationally.
Mr Bruce McHarrie has been in the biotechnology industry for over 15 years. Currently he is the Director of Finance and Business Development at the Telethon Institute for Child Health Research in Western Australia. He is responsible for the executive management of the Institute with a particular focus on commercialisation activities. Mr McHarrie joined the Institute in 1999 after returning to Western Australia from the UK, where he was Assistant Director in the Bioscience Unit at Rothschild Asset Management. The Bioscience Unit focused on investing in biotechnology and healthcare companies from the early start-up stage through to the publicly listed stage. In this capacity Mr McHarrie was invited to join the Board of a number of United Kingdom based biotechnology companies. Prior to joining Rothschild Asset Management Mr McHarrie was with Coopers and Lybrand in London, servicing a client base primarily in the financial services industry. He holds a Bachelor of Commerce Degree from the University of Western Australia and qualified as a Chartered Accountant with Deloittes.
Mr Nick Woolf has over 15 years of experience in the biotechnology sector, working both in industry and investment banking. Most recently, he was Chief Business Officer at Oxford BioMedica plc, a leading UK gene therapy company. Previously, Mr Woolf was a highly rated biotechnology equity analyst in Europe. Prior to joining Oxford BioMedica, he worked at ABN AMRO as Head of European Biotechnology Research and held similar roles at BancAmerica Robertson Stephens, Nomura and SBC Warburg. Mr Woolf is a qualified accountant and has an MA in Chemistry from the University of Oxford.
MANAGEMENT Dr Paul Michael Watt BSc(Hons) D Phil Nick Woolf Richard Hopkins Richard Hopkins completed his PhD in Molecular Parasitiology before taking up a postdoctoral appointment in yeast genetics at the Institute for Child Health Research in Wetsern Australia. His work focussed on development of a novel class of peptides, referred to as Phylomers, and the methods to integrate them into various high throughput screening platforms such as yeast two hybrid and phage display. More recently his work has focussed on engineerign peptide leads for drug development. Dr Hopkins has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications, several of which have been issued in the US and Europe. Dr Hopkins is a founding member of Phylogica and is currently employed Chief Operating Officer and VP Research. |
|
 |
Nick Woolf